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ABSTRACT 
Purpose: Between September 20,1995 and September 20, 1996, 120 patients were entered into 
a prospective, randomized trial comparing tacrolimus and prednisone with (61) and without (59) 
2 gm. mycophenolate mofetil daily to determine whether mycophenolate mofetil was associated 
with a lower incidence of rejection, 
Materials and Methods: Mean recipient age plus or minus standard deviation was 50.8 = 14.1 
years (range 18.8 to 84.1). Mean donor age was 34.3 = 21.7 years (range 0.01 to 76). Of the donors 
18 (15%) were older than 60 years. Mean cold ischemia time was 30.9 = 8.4 hours (range 14.2 to 
49). Median followup was 8.6 = 0.5 months. 
Results: The 6-month actuarial patient survival was 95%, 92% in the double therapy group and 
98% in the triple therapy group (not significant). The 6-month actuarial graft survival was 88%, 
84% in the double therapy group and 92% in the triple therapy group (not significant). The 
overall incidence of rejection and steroid resistant rejection was 34.2 and 4.2%, respectively. 
There was a strong trend toward less rejection in the mycophenolate mofetil group than in 
the double therapy group (26.2 versus 42.4%), Crossover was common, and was 42.6% from triple 
to double therapy and 18.6% from double to triple therapy. The reasons for discontinuation of 
mycophenolate mofetil were gastrointestinal toxicity, primarily diarrhea, or less commonly 
hematological toxicity, primarily neutropenia or thrombocytopenia. Gastrointestinal toxicity was 
ameliorated by separating the doses oftacrolimus and mycophenolate mofetil by 2 to 4 hours, and 
reducing the dose to 1 gm. daily. 
Conclusions: Mycophenolate mofetil appears to be a useful third agent with tacrolimus in 
patients undergoing renal transplantation, and is associated with a reduction in the rate of 
rejection and a low incidence of steroid resistant rejection. There is a high incidence of gastro-
intestinal toxicity associated with the 2 gm. daily dose but this complication is relatively 
straightforward to manage. 
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Although renal transplantation under tacrolimus based 
immunosuppression has been associated with excellent short 
and medium-term outcomes,1-7 some of the earlier studies, 
particularly those not using induction antilymphocyte prep-
arations, have described relatively high rates of early acute 
rejection ranging from 50 to 60%.8-12 While the majority of 
these rejection episodes have been steroid responsive, pa-
tients with steroid resistant rejection have had markedly 
inferior outcomes with a 3-year actuarial graft survival of 
53%.2 An early study which looked at azathioprine as a third 
agent demonstrated a modest reduction in the incidence of 
rejection and steroid resistant rejection from 55 to 45% and 
14 to 8%, respectively.1.2 Unfortunately, overall graft sur-
vival was not improved, and was actually worse at 3 years in 
patients not receiving azathioprine (76 versus 84% of pa-
tients randomized to double therapy).2.3 
having been evaluated in 3 large prospective, randomized 
trials with cyclosporine based immunosuppression.1 3-1 6 In 
these trials the incidence of early acute rejection was reduced 
significantly from 41 to 17 to 20%, although the I-year pa-
tient and graft survival rates were unaffected. In an attempt 
to determine whether mycophenolate mofetil would offer 
similar benefits with tacrolimus based therapy, we began a 
prospective, randomized trial of tacrolimus and prednisone 
with and without mycophenolate mofetil in adult renal trans-
plant recipients. Azathioprine was not used in the control 
group because of the inferior outcomes noted in an earlier 
randomized trial,2·3 In this initial report we evaluate the first 
year of the trial with a relatively short followup, since as yet 
there are no clinical reports on the combination oftacrolimus 
and mycophenolate mofetil in a randomized trial. 
PATIENTS AND METHODS A new azathioprine substitute, mycophenolate mofetil, was 
approved by the Food and Drug Administration in June 1995, 
Recipient and donor characteristics. Between September 
20, 1995 and September 20, 1996, 120 adult patients under-
going first or second cadaveric kidney transplantation only 
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were entered into a prospective, randomized open label trial 
oftacrolimus and prednisone only (59) versus tacrolimus and 
prednisone with mycophenolate mofetil (61, table n Induc-
tion antilymphocyte therapy was not used. Pediatric pa-
tients, those undergoing the third or greater transplantation, 
those receiving concomitant multiple organs including bone 
marrow augmentation, those receiving kidneys from living 
donors and those refusing to consent were excluded from the 
trial. Mean recipient age was 50.8 ::: 14.1 years (range 18.8 to 
84.1). Of the patients 17 (14.2C7c) were undergoing the second 
transplantation and 11 (9.2C:C) had previously received a liver 
(10) or heart (1) allograft. Four patients (3.3%) were sensi-
tized with a panel reactive antibody level greater than 40%, 
and 38 (31.7%) were older than 60 years at the time of 
transplantation. 
Mean donor age was 34.3 = 21.7 years (range 0.01 to 76). 
Of the transplants 16 (13%) were pediatric en bloc kidneys 
from donors 3 years old or younger. Of the donors 18 (15%) 
were older than 60 years. ~fean cold ischemia time was 
30.9 ::: 8.4 hours (range 14.2 to 49). Cold storage preservation 
was used. Mean number of human leukocyte antigen 
matches and mismatches was 2.6 ::: 1.2 and 3.1 ::: 1.3, re-
spectively. There were 7, 0 antigen mismatched cases (5.8%). 
Immunosuppression. A dose of 0.15 mg./kg. tacrolimus was 
given orally to all patients preoperatively. In the recovery 
roo~ or intensive care unit 0.025 to 0.05 mg./kg./24 hours 
intravenous tacrolimus was given as a continuous infusion. 
Wher patients were able to tolerate oral medications 0.15 
mg./kg. tacrolimus orally tv.;ce a day was begun and intra-
venous tacrolimus was tapered off in 0 to 48 hours. Further 
dosage adjustments were guided by levels. Target tacrolimus 
levels by whole blood IMx, were 20 to 25 ng./ml., for the first 
2 weeks, 15 to 20 at 1 month, 10 to 15 at 3 months and 5 to 
12 chronically. 
Steroids. All patients received intraoperatively 1,000 mg. 
methylprednisolone intravenously and a short steroid taper 
from 200 to 20 or 30 mg. daily for 6 days. Further tapering 
was individualized but in the ideal case the prednisone dose 
was decreased to 15 mg. daily by 3 to 4 weeks and then by 2.5 
mg. decrements to 10 mg. daily by 2 to 3 months after 
transplantation. Thereafter the prednisone dose was de-
creased by 2.5 mg. every 4 to 6 weeks until it was completely 
discontinued, if possible. 
Mycophenolate mofetil. Patients randomized to receive my-
cophenolate mofetil were given 1,000 mg. orally preopera-
tively and started on 1,000 mg. orally twice a day beginning 
on postoperative day 1. After the first few months of the 
study tacrolimus and mycophenolate mofetil dosages were 
separated by 3 to 4 hours, which significantly improved the 
tolerability of the combination of the 2 agents. In the case of 
adverse events, for example diarrhea, gastritis, leukopenia or 
thrombocytopenia, the mycophenolate mofetil dose was gen-
erally decreased to 500 mg. orally twice a day. If side effects 
persisted, mycophenolate mofetil was discontinued. 
Rejection. More than 95% of rejection episodes were biopsy 
proved and routinely treated with a steroid bolus (1,000 mg. 
intravenous methylprednisolone) and short recycle with aug-
mentation of the tacrolimus dosage. For steroid resistant 
rejection 5 mg. OKT3 was given intravenously daily for 10 to 
14 days. Patients randomized to double therapy were crossed 
over to receive mycophenolate mofetil if moderate acute or 
steroid resistant rejection developed. Sporadically, 500 mg) 
kg. immunoglobulin x 4 was administered intravenously for 
refractory rejection, 17. 18 that is in patients who had persis-
tent rejection despite steroids, OKT3 and crossover to myco-
phenolate mofetil. 
Randomization and statistical analysis. Continuous vari-
ables are presented as mean plus or minus standard deviation 
and categorical variables as proportions. Randomization was 
done by sequential draw of assignment using a variable block 
randomization scheme. 19 The block sizes varied (4 or 6) and 
were selected with equal probability. The order of assignment 
within a block was determined by generating a random number 
between 0 and 1, and then rearranging the random numbers in 
ascending order. Baseline characteristics of the patient popula-
tion were compared using the standard 2-sample t test for 
continuous data and Pearson's chi-square test for categorical 
data. 
Patient survival was calculated from the date of kidney trans-
plantation until death and graft survival from the date of kid-
ney transplantation until graft failure, re-transplantation or 
patient death. Survival curves were generated using the 
Kaplan-Meier (product limit) method20 and compared by the log 
rank (Mantel-Cox) test.21 All analyses were performed accord-
ing to intention to treat using computer software. All tests were 
2-tailed and p <0.05 was considered statistically significant. 
Although no investigational agents were used, approval by the 
Health Sciences Institutional Review Board of the University of 
Pittsburgh was obtained with yearly renewal because of the 
randomized nature of the trial. 
RESULTS 
Median followup was 8.6 months, which was too short to 
allow for calculation of I-year actuarial patient and graft 
survival statistics. The 6-month actuarial patient survival 
was 95%, 92% in the double therapy group and 98% in the 
triple therapy group (not significant). The 6-month actuarial 
graft survival was 88%, 84% in the double therapy group and 
92% in the triple therapy group (not significant). The overall 
incidence of rejection and steroid resistant rejection was 34.2 
and 4.2%, respectively (table 2). There was a strong trend 
TABLE 1. Recipient and donor characteristics 
No. pts. 
~1ean reCIpient age ~ SO (rangel 
t-:o. second transplantation I C( 1 
~oK panel reactive antibodies 
greater than 40'"" (<;;. 1 
t-:o. previous Jiver or heart I,",,) 
;\;0. recipient age greater than 60 
yrs. tr'f) 
Mean donor age ~ SO (range) 
No. en bloc donor 3 years or 
younger (r.( 1 
1';0. donor older than 60 vrs. I,",,) 
Mean ischemia time ~ S·O (hrs.1 
Mean human leukocyte antigen 
match ~ SO 
Mean human leukocyte antigen 
mismatch :: SO 
No. 0 antigen mISmatch I r.() 
Tacrolimus - Prednisone 
59 
54.0 ~ 13.11193-8411 
6 110.2) 
2 13.4) 
5 
22 
18.5) 
137.31 
33.8 ~ 20.9 10.3-70.0) 
10 116.91 
8 
29.5 ~ 8.5 
2.6 :: 1.3 
3.1 ~ 1.4 
3 
113.6) 
15.li 
Tacrolimus + Prednisone - Mycophenolate Mofetil 
61 
47.7 :: 14.5 (18.8--717). P <002 
11 118.0) 
2 /3.3) 
6 
16 
19.81 
126.2) 
34.7 :!: 22.6 W.01-76.0) 
6 19.8) 
10 
32.3 ~ 8.2 
2.6 :!: 1.2 
3.1 :: 1.3 
4 
116.4) 
(66) 
Overall 
120 
50.8 :': 14.1 (18.8-84.11 
17 114.2) 
4 13.3) 
11 
38 
19.2) 
131.7) 
34.3 :!: 21.7 \O.Dl-76 0) 
16 113.3) 
18 
30.9 :': 8.4 
2.6 :!: 1.2 
3.1:': 1.3 
i , 5.81 
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TABLE 2. Results 
Rejection 
Steroid resistant rejection 
Delayed graft function 
Cytomegalovirus 
Post·transplantation diabetes mellitus 
Crossover 
7, Tacrolimus ... Prednisone 
42.4 
6.8 
22 
5.1 
10.9 
18.6(2-3) 
toward less rejection in the mycophenolate mofetil group 
than in the double therapy group 126.2 versus 42.4%). There 
was also a trend toward less steroid resistant rejection in the 
mycopheno~ate mofetil group (1.6 versus 6.8%), In the pa-
tients who never discontinued mycophenolate mofetil the 
incidences of rejection and steroid resistant rejection were 14 
and 0%, respectively (table 3). 
The incidence of asymptomatic or symptomatic cytomega-
lovirus was 12.5%, and was higher in the mycophenolate 
mofetil group than in the double therapy group 09.7 versus 
5.1%, p <0.03, table 2). Cytomegalovirus was treated with 
intravenous ganciclovir and reduction of immunosuppression 
until the antigenemia level decreased to zero. There were no 
serious cytomegalovirus related complications. Prophylatic 
high dose oral acyclovir was given to seropositive recipients. 
Seronegative recipients of seropositive organs received either 
ganciclovir and cytomegalovirus hyperimmune globulin or no 
prophylaxis with frequent antigenemia screening as part of a 
separate randomized trial. 
Post-transplantation lymphoproliferative disorder occurred 
in a 57-year-old sensitized woman who was randomized to 
double therapy but received OKT3 and mycophenolate 
mofetil on postoperative day 1 because of suspected antibody 
mediated rejection. She eventually achieved normal renal 
n:ncti~n but multiple nodules of pulmonary lymphoprolifera-
tlVe dIsorder developed 9 months after transplantation. She 
was treated with cessation of tacrolimus and mycophenolate 
mofetil, intravenous ganciclovir and lymphokine activated 
killer cell therapy,22 with regression of the lesions and ini-
tially stable renal function. The patient returned to dialysis 3 
months later. 
There was no significant difference between the 2 groups in 
delayed graft function (25%, table 2) or initial post-
transplantation diabetes (9.6%), which was lower than that 
reported in earlier trials. 1.6. 7 The routine management of 
this latter complication has involved gradual reduction of the 
tacrolimus and prednisone dosages. Historicallv 50% of our 
patients have been able to discontinue insulin 'after the de-
crease in dosage. I Followup was too short to determine the 
final incidence of post· transplantation diabetes in this series. 
Crossover between the 2 groups was common. In 42.6% of 
patients randomized to triple therapy mycophenolate mofetil 
was discontinued at 1 time or another (table 2). The most 
common reason was gastrointestinal toxicity, principally di-
arrhea. and occasionally gastritis. which was believed to be 
related to mycophenolate mofetil because it was generally 
not seen in patients randomized to double therapy. Hemato-
logical toxicity, principally neutropenia or thrombocytopenia, 
was another cause of crossover. Viral infection with cytomeg-
alovirus, Epstein-Barr virus or polyoma (BK) virus was the 
TABLE 3. Results of rejection and steroid resistant rejection in the 
triple therapy group 
No. pts. 
% Rejection 
% Steroid resis· 
tant rejection 
Discontinued 
Mycophenolate 
Mofetil 
:-lever Discontinued 
Mycophenolate 
~lofetil 
35 
14 
o 
Overall 
q Tacrolimus .,. Prednisone + Mycophenolate Mofetil 
26.2 
1.6 
28 
19.7 (p <0.03) 
8.3 
42.6 13-2)(p <0.0051 
'70 Overall 
other main indication for crossover. Even in the absence of 
crossover reduction of the mycophenolate mofehl dose to 500 
mg. orally twice a day was common, mainly for gastrointes-
tinal toxicity. The incidence of crossover declined from the 
first to the second 6 months of the trial from 48.5 to 35.7%. 
Mycophenolate mofetil was added because of rejection III 
18.6% of patients randomized to double therapy. 
DISCUSSION 
We have used tacrolimus as a primary immunosuppressive 
agent in our patients undergoing renal transplantation since 
1989, and have been impressed with the overall immunosup-
pressive efficacy, improved half-life, ability to allow steroid 
withdrawal in the majority of patients with successful trans-
plants, lower cholesterol levels and lower incidence ofhyperten-
sion.1- 12 However, the incidence of early acute rejection in our 
patients, who have not as a rule received induction antilympho-
cyte therapy, has been relatively high.s-12 The consequences of 
steroid resistant rejection have been frankly disappointing.2•3 
Thus, we have considered possible third agents with the goal of 
reducing the rate of rejection, and possibly improving overall 
patient and graft survival. Although azathioprine was associ-
ated with somewhat less rejection, the overall poorer outcomes 
associated with its use rendered it a poor candidate for routine 
use as a third agent.2.3 Antilymphocyte induction has not been 
used routinely in our program because of concerns about over 
immunosuppression. In view of the favorable outcomes 
achieved vvith mycophenolate mofetil and cyclosporine based 
regimens,13-16 we thought that it would be worthwhile to eval-
uate mycophenolate mofetil with tacrolimus. 
The preliminary findings suggest that a lower incidence of 
rejection is achievable with mycophenolate mofetil, and with 
a greater accrual of patients we would expect to see a statis· 
tically significant reduction in rejection. The gastrointestinal 
a?d hematological complications seem not to be excessively 
dfffic~lt to manage. Separating the timing of the 2 agents and 
reducmg the dosage of mycophenolate mofetil have usually 
been successful: and the rate of crossover from triple to 
double therapy m the second 6 months of the trial was less 
tha~ in the first 6 months. The higher incidence of cytomeg-
alOVIrus IS of some concern but the explanation may be that 
the 5. ~ % incidence of cytomegalovirus in the double therapy 
group IS perhaps unusually low, rather than the incidence in 
the triple therapy group being particularly high. Of note, our 
overall preliminary findings are similar to those of Roth et aI, 
who have reported their retrospective, nonrandomized expe-
rience with tacrolimus and mycophenolate mofetil. 23 They 
have reported even less rejection in patients receiving mycon-
phenolate mofetil (8 versus 21% of patients not receiving 
myconphenolate mofetill presumably because of the routine 
use of antibody induction. 
In conclusion, we are encouraged by the combination of 
tacrolimus and mycophenolate mofetil, and expect that the 
associated toxicities will be manageable, in return for a sub-
stantial reduction in the incidence of acute rejection. Longer 
followup will be necessary to determine whether there will be 
an improvement in patient or graft survival. 
Regina Fenton, Loraine Oczypok. Deborah Good. Holly 
Woods, Jareen Flohr, Sue Bauder, Jennifer Ovesney, Sharon 
Orlofske. Mark Paynter, and Gerri James assisted with pa-
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EDITORIAL COMMENT 
The estimated half-life of renal allografts is shorter for recipients 
who have acute rejection episodes compared to those who do not. 
Mycophenolate mofetil is associated with a 60 to 70% decrease in 
acute rejection episodes.!. 2 Thus, it is hopeful that this immunosup-
pressive drug will also increase long-term half-life allograft survival 
in kidney recipients. This hope is driven by encouraging results from 
several large studies (reference 15 ofarticlel.2 The authors present a 
randomized, prospective trial of 120 patients comparing 2 tacrolimus 
based regimens with (61) and without (59) 2 gm. mycophenolate 
mofetil daily. The groups were similar in all characteristics except 
for recipient age as the mycophenolate mofetil group was younger 
than the double therapy group (47.7 versus 54 years, p <0.02). 
Nevertheless, other characteristics seemed different but were not 
statistically significant (second transplantation 10.2 versus 18%, 
recipients older than 60 years 37.3 versus 26.2%, donors younger 
than 3 years old with en bloc kidneys 16.9 versus 9.8% and cold 
ischemia hours 29.5 versus 32.3, respectively, with and without 
mycophenolate mofetil). Medium followup was short (8.6 :: 0.5 
months) and the data were reported in terms of 6-month actuarial 
graft survival (84 versus 92% with and without mycophenolate 
mofeti!). Rejection rates were 42.4 versus 26.20/( and steroid resistant 
6.8 versus 1.6%, respectively, with and without mycophenolate 
mofetil. None of these comparisons approached statistical signifi-
cance. However, there were significant increases in complications 
reported in the mycophenolate mofetil group (19.7 versus 5.10/(, p 
<0.03) for cytomegalovirus and 42.6 versus 18.60/( (p <:0.005) cross-
ing over predominantly because of gastrointestinal toxicity. 
While this study was randomized and prospective, it was not 
blinded. There are many factors that can significantly dilute the 
results so that significance is not seen, as in many other studies 
comparing cyclosporine double therapy to that with the same regi-
men containing mycophenolate mofetil. These factors mav be the 
inclusions of patients with heart/kidney and liverlkidney tra~sp!ants 
who are different immunologically from those who have received 
kidney transplants only. Another factor that can confuse the results 
is the crossover from the mycophenolate mofetil group mainly be-
cause gastrointestinal toxicity. Gastrointestinal toxicity was noted to 
be much more serious than in other nontacrolimus, that is cyclospor-
ine A. studies. which may reflect on a potential synergistic effect that 
mycophenolate mofetil and tacrolimus have on the gastrointestinal 
tract. The European Mycophenolate Mofetil Cooperative Study 
Group reported only a 17.60/: withdrawal rate due to adverse events 
in 165 patients on similar 2 gm. mycophenolate mofeti! dailyK~ Al-
though it is stated that these symptoms can be "relatively straight 
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forward to manage." a significant consequence of gastrointestinal 
toxicity is inadequate absorption of medications and. thus. subopti-
mal immunosuppression. perhaps contributing to greater rejection 
risk. The authors noted that the trend towards less rejection was not 
significant. Unfortunately. these preliminary findings may not have 
the statistical power to offer definitive conclusions. Finally. the rel-
atively low graft survival noted in a short followup (gold standard for 
followup is I-year graft survival) is of major concern, since graft loss 
at 1 year should be predictably greater. 
Nevertheless, this study offers a large experience with the use of 
tacrolimus and mycophenolate mofetil although the data are difficult 
to assess and it is too soon to deri\'e assumptions. It is apparent that 
mycophenolate mofetil and tacrolimus compared to mycophenolate 
mofetil and cyclosporine2 are associated with greater gastrointesti-
nal toxicity and cytomegalovirus infections. Whether this difference 
justifies the possibility of better acute rejection prevention remains 
to be seen. I agree with the authors that longer followup is necessary. 
Peter N Bretan. Jr. 
Renal Transplant Service 
University of California. San Francisco Medical Center 
San Francisco, CalLfornia 
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